Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Conditions:   Hypertrophic Cardiomyopathy;   Myocardial Perfusion Imaging
Intervention:   Diagnostic Test: myocardial perfusion imaging
Sponsor:   Far Eastern Memorial Hospital
Recruiting - verified May 2017

Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy

Conditions:   Ventricular Tachycardia;   Ischemic Cardiomyopathy;   Reduced LVEF
Interventions:   Procedure: VT ablation;   Other: medication
Sponsor:   Heinrich-Heine University, Duesseldorf
Recruiting - verified May 2017

SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure

Conditions:   Medication Adherence;   Heart Failure;   Aging
Intervention:   Behavioral: SystemCHANGE
Sponsor:   University of Missouri, Kansas City
Not yet recruiting - verified May 2017

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

Conditions:   Cardiotoxicity;   Heart Failure;   Breast Cancer;   Anthracycline Induced Cardiomyopathy;   Biomarkers;   Echocardiography
Intervention:  
Sponsors:   Stony Brook University;   Gilead Sciences
Recruiting - verified May 2017

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Condition:   Heart Failure With Preserved Ejection Fraction
Interventions:   Drug: Macitentan;   Drug: Placebo
Sponsor:   Actelion
Not yet recruiting - verified May 2017

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2017

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Condition:   Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified May 2017

The PARTNER 3 - AVIV Trial

Conditions:   Aortic Stenosis;   Cardiomyopathy, Hypertrophic
Intervention:   Device: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Sponsor:   Edwards Lifesciences
Recruiting - verified April 2017

Anakinra Versus Placebo for the Treatment of Acute MyocarditIS

Condition:   Acute Myocarditis
Interventions:   Drug: ANAKINRA 100 mg/daily subcutaneously;   Drug: Placebo
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified May 2017

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

Conditions:   Iron Deficiency;   Heart Failure
Interventions:   Drug: ferric carboxymaltose;   Other: Normal saline 0.9%
Sponsors:   Vifor Inc.;   Worldwide Clinical Trials;   Cytel Inc.
Recruiting - verified September 2016

Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis

Condition:   Patients With Suspected Acute Myocarditis
Intervention:   Procedure: Spectral cardiac CT scan
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified April 2017

MOMENTUM 3 Continued Access Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Intervention:   Device: HeartMate 3 LVAS
Sponsors:   St. Jude Medical;   Thoratec, LLC
Recruiting - verified May 2017

Coronary Sinus Blood Sevoflurane and Desflurane Concentration and Lactate Changes in Patients Undergoing Heart Surgery

Conditions:   Myocardial Reperfusion Injury;   Heart Diseases;   Postoperative Complications
Intervention:   Biological: Blood samples
Sponsors:   University of Malaya;   University of Edinburgh
Not yet recruiting - verified August 2016

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified May 2017

Molecular Imaging of Primary Amyloid Cardiomyopathy

Conditions:   Amyloidosis, Primary;   Cardiomyopathy
Interventions:   Radiation: F-18 florbetapir/C-11 acetate PET;   Device: MRI;   Radiation: N-13 ammonia PET
Sponsors:   Brigham and Women's Hospital;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   American Heart Association
Recruiting - verified May 2017

Characterization of Obesity-related Cardiomyopathy Through Exploration of Human Atrial Trabeculae Contraction

Conditions:   Obesity;   Heart Failure
Intervention:   Other: functional tissu atrial analysis
Sponsor:   University Hospital, Lille
Recruiting - verified May 2017

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Conditions:   Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC);   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related;   Familial Transthyretin Cardiac Amyloidosis
Interventions:   Drug: Revusiran (ALN-TTRSC);   Drug: Sterile Normal Saline (0.9% NaCl)
Sponsor:   Alnylam Pharmaceuticals
Completed - verified May 2017

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

Condition:   Friedreich's Ataxia
Interventions:   Procedure: Cardiac magnetic resonance imaging (CMR);   Procedure: Exercise-stress test;   Procedure: Echocardiogram (ECHO);   Procedure: Cardiac-related blood studies
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified May 2017

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Condition:   TTR-mediated Amyloidosis
Intervention:   Drug: Revusiran (ALN-TTRSC)
Sponsor:   Alnylam Pharmaceuticals
Completed - verified May 2017

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Procedure: Noncontrast echocardiography;   Procedure: Contrast Echocardiography;   Procedure: Cardiac magnetic resonance imaging
Sponsors:   Mayo Clinic;   GE Healthcare
Recruiting - verified May 2017

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsors:   Thoratec Corporation;   St. Jude Medical
Active, not recruiting - verified May 2017

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.

Conditions:   Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency;   Carnitine-acylcarnitine Translocase (CACT) Deficiency
Intervention:   Drug: UX007
Sponsor:   Ultragenyx Pharmaceutical Inc
Enrolling by invitation - verified May 2017

A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Condition:   LMNA-Related Dilated Cardiomyopathy
Intervention:   Drug: ARRY-371797, p38 inhibitor; oral
Sponsor:   Array BioPharma
Completed - verified May 2017

ACAM2000® Myopericarditis Registry

Conditions:   Myocarditis;   Pericarditis
Intervention:  
Sponsor:   Sanofi Pasteur, a Sanofi Company
Active, not recruiting - verified May 2017

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions:   Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention:   Other: None. Observational Study.
Sponsor:   Pfizer
Recruiting - verified May 2017